Aprea Therapeutics Inc (APRE) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-0.52x
Aprea Therapeutics Inc (APRE) has a Cash Flow-to-Debt Ratio of -0.52x as of March 2026, meaning its operating cash flow of $-2.76 Million could theoretically repay -1% of its total liabilities ($5.30 Million) in one year. See Aprea Therapeutics Inc (APRE) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.52x
Operating CF / Total Liabilities
Operating Cash Flow
$-2.76 Million
USD
Total Liabilities
$5.30 Million
USD
Data as of
Mar 2026
Most recent filing
Aprea Therapeutics Inc Cash Flow-to-Debt Ratio (2007–2025)
Historical debt coverage capacity for Aprea Therapeutics Inc across 10 annual periods. For the full cash flow conversion analysis, see APRE operating cash flow.
Annual Cash Flow-to-Debt Ratio for Aprea Therapeutics Inc (2007–2025)
Year-by-year debt coverage analysis for Aprea Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.69x | $-12.89 Million | $3.49 Million | ▼ -27.3% |
| 2024 | -2.90x | $-13.56 Million | $4.67 Million | ▼ -4.5% |
| 2023 | -2.78x | $-12.18 Million | $4.39 Million | ▲ +49.9% |
| 2022 | -5.54x | $-25.01 Million | $4.51 Million | ▼ -7.6% |
| 2021 | -5.15x | $-37.69 Million | $7.32 Million | ▼ -89.9% |
| 2020 | -2.71x | $-41.80 Million | $15.41 Million | ▲ +4.9% |
| 2019 | -2.85x | $-26.71 Million | $9.36 Million | ▼ -2096.8% |
| 2018 | -0.13x | $-15.25 Million | $117.46 Million | ▲ +43.9% |
| 2017 | -0.23x | $-14.00 Million | $60.53 Million | ▲ +70.4% |
| 2007 | -0.78x | $-1.90 Million | $2.43 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.